Group 1: Apple Store Closures and Openings - Apple will close its first official retail store in China, the Dalian Century City store, on August 9, 2023, due to multiple retailers leaving the shopping center [1] - The Dalian store opened on October 24, 2015, and is the first Apple Store to shut down in the country [1] - Apple plans to open a new retail store in Shenzhen on August 16, 2023, marking its third store in the city [1] Group 2: Legal Challenges - Apple has issued a strong statement against the U.S. Department of Justice (DOJ) regarding antitrust lawsuits, claiming all 236 allegations are unfounded [2] - The lawsuit threatens the core principles that allow the iPhone to stand out in a competitive market, according to Apple [2] - Apple is expected to engage in a prolonged legal battle, with the potential for a resolution taking several years [2] Group 3: Financial Partnerships - Apple is reportedly in talks with JPMorgan Chase to take over the Apple Card credit card business from Goldman Sachs [3] - Negotiations between Apple and JPMorgan began in early 2022, with recent developments accelerating the process [3] - Although no agreement has been signed yet, Goldman Sachs has hinted at the possibility of ending the partnership before the original contract expiration in 2030 [4] Group 4: Securities Fraud Allegations - Apple faces a new class-action lawsuit related to delays in the upgrade of its Siri digital assistant, which has been postponed to after iOS 18 [5] - The Rosen Law Firm is seeking investors who purchased Apple securities between June 10, 2024, and June 9, 2025, to join the lawsuit [5] Group 5: Real Estate Investments - Apple has signed a deal to acquire the Mathilda campus in Sunnyvale for $365 million, marking its third major real estate transaction in the Bay Area this year [6] - The total investment for office space expansion in the Bay Area over the past three months approaches $882 million [6] - Despite high vacancy rates in the tech industry, Apple continues to expand its office space in the Bay Area [6]

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

WHAT'S NEXT? If you suffered a loss in iRobot Corporation during the relevant time frame, you have until September 5, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & ...

WHAT'S NEXT? If you suffered a loss in Flywire Corporation during the relevant time frame, you have until September 23, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. CLASS DEFINITION: The lawsuit seeks to recover losses on behal ...

BENSALEM, Pa., July 30, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE SEPTEMBER 22, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howar ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38% from $12.79 to $7.95 per share [6].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices [1][3] Company Overview - GeneDx Holdings Corp. is under scrutiny following a report by Grizzly Research alleging widespread fraud, claiming that the company's growth is artificially inflated through illegal practices targeting Medicaid and Medicare [3] - The report specifically mentions "code stacking" as a method used by GeneDx to bill insurance providers for services that do not meet required criteria [3] Stock Performance - Following the allegations, GeneDx's stock price dropped by $4.84, or 6.72%, closing at $67.18 per share on February 5, 2025 [3]

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus AI's joint venture with SoftBank Group Corporation, suggesting it created an appearance of "round-tripping" capital to inflate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is alleged to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca PLC reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising further concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised multiple red flags regarding Tempus AI's management, operations, and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Tempus AI common stock during the specified Class Period to seek appointment as lead plaintiff in the class action lawsuit [5]. - A lead plaintiff is typically the investor with the greatest financial interest in the case and acts on behalf of all other class members [5]. - Investors can choose their own law firm to represent them in the lawsuit, and participation as lead plaintiff does not affect their ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating its strong track record in obtaining monetary relief for investors [6].

https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=158421&wire=4 RXST investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, R ...